Loading clinical trials...
Loading clinical trials...
A Seamless Phase 2/3 Randomized, Open-label Study to Investigate Efficacy and Safety of Frexalimab Versus Tacrolimus in Adult Kidney Transplant Recipients
Conditions
Interventions
Frexalimab
Frexalimab
+6 more
Locations
2
Australia
Investigational Site Number : 0360003
Sydney, Australia
Investigational Site Number : 1560001
Shanghai, China
Start Date
March 13, 2026
Primary Completion Date
August 15, 2029
Completion Date
August 15, 2033
Last Updated
March 27, 2026
NCT07006532
NCT04736381
NCT04702022
NCT06100965
NCT06825117
NCT04953715
Trial Transparency email recommended (Toll free for US & Canada)
CONTACT
800-633-1610Contact-US@sanofi.comLead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions